IRVING, Texas - McKesson Corporation (NYSE: NYSE:MCK), a leader in healthcare services, reported lower-than-expected earnings and revenue for its fiscal 2024 fourth quarter, sending shares down 2.4%.
The company posted adjusted earnings per share (EPS) of $6.18, falling short of the analyst consensus of $6.36. Revenue also missed expectations, coming in at $76.36 billion against the forecasted $79.35 billion.
The company's financial performance for the quarter was impacted by both earnings and revenue not meeting analyst estimates, which drove the stock price down following the announcement. Despite this quarter's results, McKesson provided guidance for fiscal year 2025 with an EPS range of $31.25 to $32.05, slightly above the consensus estimate of $31.02.
McKesson's management reflected on the quarterly results with a focus on their commitment to advance health outcomes and provide value to their partners across the healthcare spectrum. "While we faced challenges this quarter, our strategic initiatives continue to position us well for delivering long-term growth," said a company spokesperson.
Looking ahead to fiscal year 2025, McKesson's midpoint guidance of $31.65 is marginally higher than analysts' predictions, suggesting a potential rebound in investor confidence as future prospects are weighed against current performance metrics.
As McKesson navigates through these challenges, its role in delivering healthcare services remains critical amidst an evolving industry landscape. The company's financial health will be closely monitored by investors as they assess McKesson’s ability to meet its guidance and adjust strategies accordingly.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.